Ensol Biosciences (XKRX:140610) Debt-to-Equity : -1.57 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences Debt-to-Equity?

Ensol Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩8,277.6 Mil. Ensol Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩256.4 Mil. Ensol Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₩-5,452.2 Mil. Ensol Biosciences's debt to equity for the quarter that ended in Dec. 2023 was -1.57.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Ensol Biosciences's Debt-to-Equity or its related term are showing as below:

XKRX:140610' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.91 Med: 0.01 Max: 2.29
Current: -1.57

During the past 10 years, the highest Debt-to-Equity Ratio of Ensol Biosciences was 2.29. The lowest was -2.91. And the median was 0.01.

XKRX:140610's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs XKRX:140610: -1.57

Ensol Biosciences Debt-to-Equity Historical Data

The historical data trend for Ensol Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences Debt-to-Equity Chart

Ensol Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.08

-1.39

-2.91

-1.31

-1.57

Ensol Biosciences Semi-Annual Data
	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Debt-to-Equity	Get a 7-Day Free Trial					1.08	-1.39	-2.91	-1.31	-1.57

Competitive Comparison of Ensol Biosciences's Debt-to-Equity

For the Biotechnology subindustry, Ensol Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ensol Biosciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensol Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Ensol Biosciences's Debt-to-Equity falls into.

Ensol Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Ensol Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(8277.62	+	256.442)	/	-5452.246
	=	-1.57

Ensol Biosciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(8277.62	+	256.442)	/	-5452.246
	=	-1.57

Ensol Biosciences (XKRX:140610) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Ensol Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Ensol Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ensol Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036

Website

http://www.ensolbio.co.kr

Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences Headlines

No Headlines